Bone Marrow Collection in Healthy Volunteers (iCell)

NCT ID: NCT02118740

Last Updated: 2017-01-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

15 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-06-30

Study Completion Date

2018-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a observational study in which healthy found volunteers are recruited to donate 50 ml of bone marrow aspirate to enable preclinical studies to obtain proof of concept and safety of a bone marrow derived stem cell preparation named AMARCELL. The prepared AMARCELL is only for animal studies and after completion of the preclinical program, the intention of AMARCELL is to treat humans with a traumatic Spinal cord injury.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Coded anonymized patient data

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spinal Cord Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men in the age range of 21-30 years and/or women in the age range of 21-30 years and taking birth control medication to prevent pregnancy
* Written informed consent
* Healthy as concluded by the answers given to questions in a short health questionnaire

Exclusion Criteria

* Pregnancy or lactation period
* Volunteers who are unable to comply with the rules of this project. Important is if the volunteer can not follow the schedule of the appointments.
* Abuse of alcohol, medicines or illicit drugs.
* Legally protected people
Minimum Eligible Age

20 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Neuroplast

INDUSTRY

Sponsor Role collaborator

Amarna Stem Cells BV

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Harry Steinbusch, Prof.dr.

Role: STUDY_DIRECTOR

University Maastricht

Gerard Bos, Prof.dr.

Role: PRINCIPAL_INVESTIGATOR

Maastricht University Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MUMC

Maastricht, Limburg, Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Johannes de Munter, MD

Role: CONTACT

+31-615897008

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A2013SCI-01

Identifier Type: OTHER

Identifier Source: secondary_id

NL44976.068.13

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Treatment for Acute Spinal Cord Injury
NCT00695149 TERMINATED PHASE1/PHASE2
Cord Blood Cells in Patients With Acute SCI
NCT05693181 UNKNOWN PHASE1/PHASE2
Bone Marrow Cells in Myocardial Infarction
NCT00363324 COMPLETED PHASE2/PHASE3